Results 241 to 250 of about 61,606 (334)

Biobanks need pharma [PDF]

Nature, 2009
openaire   +2 more sources

Spatial transcriptomics in epilepsy research: Early successes, opportunities, and challenges

Epilepsia, EarlyView.
Donald J. Phillips, Autumn S. Ivy, Samuel Guzman, Saman Hazany, Xiangmin Xu   +4 more
wiley   +1 more source

Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF‐PARAGON study)

International Journal of Cancer, EarlyView.
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Thorsten O. Goetze, Salah‐Eddin Al‐Batran, Ruediger Liersch, Lars Scheuer, Thomas Goehler, Ulrich Kaiser, Claudio Denzlinger, Stephan Brandl, Daniel Pink, Jens Uhlig, Michael Maasberg, Maria Loose, Marina Schaaf, Disorn Sookthai, Bianca Zäpf, Claudia Pauligk, Timursah Habibzade, Ralf‐Dieter Hofheinz, Christine Koch, for the AIO Study Group   +19 more
wiley   +1 more source

Strengthening ethical oversight in genomics and biobanking: a retrospective analysis of research practices in Zimbabwe. [PDF]

BMC Med Ethics
Kuguyo O, Matimba A, Mutevedzi F, Chimatira A, Chikwasha V, Kangwende A, Gwanzura L, Ndebele P.   +7 more
europepmc   +1 more source

Challenges in the future of cancer screening

International Journal of Cancer, EarlyView.
Abstract The purpose of cancer screening is to reduce mortality, and ideally incidence, from the cancer screened for. Until recently, cancer screening has been offered to all persons in pre‐defined sex‐ and age‐groups. The exception is lung screening which is targeted to high‐risk individuals.
Elsebeth Lynge, Berit Andersen, Stig E. Bojesen, Lone Kjeld Petersen, Mickael Bech, Martin Bøgsted, Mie Seest Dam, Søren Egstrand, Anne Mette Fløe Hvass, Camilla J. Kobylecki, Kristina Lång, Mads Nielsen, Giorgi Paolo Rossi, Michael Stenger, Ilse Vejborg, Future of Cancer Screening Working Group, Vibe Munk Bertelsen, Janne Bigaard, Karen Omann Binderup, Lennart Friis‐Hansen, Stine Bisgaard Greve, Jessica Xin Hjaltelin, Rikke Hedegaard Jensen, Gitte Jessing, Pia Kirkegaard, Mette Hartmann Nonboe, Tina Bech Olesen, Katrine Stolberg, Signe Bülow Therkildsen, Mette Kielsholm Thomsen   +29 more
wiley   +1 more source

Lung cancer biobanking in Australia: challenges and future directions. [PDF]

Med J Aust
Yeo S, Wong SQ, Atashrazm F, Behren A, Papenfuss AT, Vukelic N, Briggs L, Poh AR, Steinfort D, Smallwood N, Sutherland K, Naranbhai V, Parakh S, Leong T.   +13 more
europepmc   +1 more source

Epidemiological evidence for the role of puberty and immune senescence in Hodgkin lymphoma aetiology from 1992 Danish cases

International Journal of Cancer, EarlyView.
What's New? The understanding of the epidemiological and clinical distinctions between Epstein–Barr virus (EBV)‐positive and EBV‐negative classic Hodgkin lymphoma remains incomplete. Here, the authors generated unique sets of population‐based sex‐ and age‐specific incidence rates of classic Hodgkin lymphoma in Denmark stratified by histological subtype
Klaus Rostgaard, Stephen Hamilton‐Dutoit, Kristina L. Lauridsen, Lisa Ottander, Trine L. Plesner, Peter Hollander, Peter Brown, Lene Sjö, Christoffer Johansen, Peter Kamper, Estrid Høgdall, Francesco d'Amore, Lena Specht, Ruth F. Jarrett, James D. McKay, Martin Hutchings, Lisa L. Hjalgrim, Ingrid Glimelius, Henrik Hjalgrim   +18 more
wiley   +1 more source

Clinical feasibility and cost efficiency of perinatal mesenchymal stem cell production under GMP conditions. [PDF]

Sci Rep
Çopuroğlu M, Yalçın ÖT, Kara SG.
europepmc   +1 more source